PR92601

CAMBRIDGE, England, Oct. 27, 2021 /PRNewswire=KYODO JBN/ --

- Completing $340m strategic acquisition of BioVision

- Expanding facilities in Eugene, further growing kits and assays portfolio

- Supporting the growing demand of the sector and accelerating execution of

strategic plan

Abcam (https://corporate.abcam.com/ ) (AIM:ABC; NASDAQ:ABCM), a global

innovator in life sciences reagents and tools, today announces the successful

completion of its acquisition of BioVision and the expansion of its immunoassay

capacity in Eugene, OR.

Logo - https://mma.prnewswire.com/media/1670705/Abcam_Logo.jpg

Across the life sciences sector, the events of the last 18 months have

amplified the need for efficient workflows and robust data generation, to

enable the faster delivery of positive outcomes for science and health.

Widespread access to high-performance, reproducible, off-the-shelf assays and

kits has become invaluable to enable the biopharma industry and academia to

achieve meaningful advances at pace. To further support the growing demand of

the sector and to strengthen its position in the assay market, Abcam today

announces two significant developments, accelerating the execution of its

strategic growth plan.

The addition of BioVision enhances Abcam's in-house innovation and adds scale

to support the biochemical assay and cellular assay markets. The successful

acquisition brings BioVision's product portfolio, capabilities, and 70-strong

expert development and manufacturing teams into Abcam. The global research

community will gain ready access to this portfolio of biochemical and

cell-based assays via Abcam's global commercialization network.

Supplementing the acquisition, Abcam has doubled the footprint of its

immunoassay kit R&D and manufacturing facility in Eugene, OR. This enhanced

capacity is another component of Abcam's growth journey in the US and will

further enable its commitment to support the research and biopharma sector

globally.

Alan Hirzel, CEO at Abcam, commented: "We are delighted to welcome our new

colleagues to Abcam. Providing a platform for future growth and addition of new

product lines, the acquisition of BioVision and expansion of our Eugene

facility reinforce our commitment to the acceleration of scientific

breakthroughs. Enabling scientists to reproducibly generate the robust results

they need, faster, is essential   for the delivery of new innovations that can

positively impact us all."

Notes to Editors

About Abcam plc

As a global life sciences company, Abcam identifies, develops, and distributes

high-quality biological reagents and tools that are crucial to research, drug

discovery and diagnostics. Working across the industry, the Company supports

life scientists to achieve their mission, faster.

Abcam partners with life sciences organizations to co-create novel binders for

use in drug discovery, in vitro diagnostics and therapeutics, driven by the

Company's proprietary discovery platforms and world-leading antibody expertise.

By constantly innovating its binders and assays, Abcam is helping advance the

global understanding of biology and causes of disease, which enables new

treatments and improved health. The Company's pioneering data-sharing approach

gives scientists increased confidence in their results by providing validation,

user comments and peer-reviewed citations for its 90,000 products.

With 14 sites globally, many of Abcam's +1,600-strong team are located in the

world's leading life sciences research hubs, complementing a global network of

services and support.

To find out more, please visit www.abcam.com and  www.abcamplc.com.

SOURCE: Abcam